Download PDF
Semin Reprod Med 2011; 29(6): 522-539
DOI: 10.1055/s-0031-1293206
© Thieme Medical Publishers

Obstetric Antiphospholipid Syndrome: An Update on Pathophysiology and Management

Joseph M. Ernest1 , Paul B. Marshburn1 , William H. Kutteh2
  • 1Department of Obstetrics and Gynecology, Carolinas Medical Center, Charlotte, North Carolina
  • 2Division of Reproductive Endocrinology and Infertility, University of Tennessee Health Science Center, Memphis, Tennessee
Further Information

Publication History

Publication Date:
08 December 2011 (online)

    Permissions and Reprints

ABSTRACT

Antiphospholipid antibodies (aPLs) are acquired antibodies directed against negatively charged phospholipids, a group of inner and outer cell membrane antigens found in mammals. Obstetric antiphospholipid antibody syndrome (APS) is diagnosed in the presence of certain clinical features in conjunction with positive laboratory findings. Although obstetric APS was originally reported in association with slow progressive thrombosis and infarction in the placenta, it is most often associated with a poor obstetric outcome. In fact, obstetric APS is one of the most commonly identified causes of recurrent pregnancy loss (RPL). Thus obstetric APS is distinguished from APS in other organ systems where the most common manifestation is thrombosis. Several pathophysiological mechanisms of action of aPLs have been described. The most common histopathological finding in early pregnancy loss has been defective endovascular decidual trophoblastic invasion. Treatment with heparin and aspirin is emerging as the therapy of choice, with ∼75% of treated women with RPL and aPLs having a successful delivery compared with <50% without treatment. This review highlights the diagnostic challenges of obstetric APS, the obstetric complications associated with APS, proposed pathophysiological mechanisms of APS during pregnancy, and the management of women during and after pregnancy.

KEYWORDS

Antiphospholipid syndrome - antiphospholipid antibodies - obstetric antiphospholipid syndrome - recurrent pregnancy loss - fetal demise - unfractionated heparin - complications of pregnancy - thrombosis

REFERENCES

  • 1 De Wolf F, Carreras L O, Moerman P, Vermylen J, Van Assche A, Renaer M. Decidual vasculopathy and extensive placental infarction in a patient with repeated thromboembolic accidents, recurrent fetal loss, and a lupus anticoagulant.  Am J Obstet Gynecol. 1982;  142 (7) 829-834
    Google Scholar
  • 2 Adler R R, Ng A K, Rote N S. Monoclonal antiphosphatidylserine antibody inhibits intercellular fusion of the choriocarcinoma line, JAR.  Biol Reprod. 1995;  53 (4) 905-910
    Google Scholar
  • 3 Katsuragawa H, Kanzaki H, Inoue T, Hirano T, Mori T, Rote N S. Monoclonal antibody against phosphatidylserine inhibits in vitro human trophoblastic hormone production and invasion.  Biol Reprod. 1997;  56 (1) 50-58
    Google Scholar
  • 4 Quenby S, Mountfield S, Cartwright J E, Whitley G S, Chamley L, Vince G. Antiphospholipid antibodies prevent extravillous trophoblast differentiation.  Fertil Steril. 2005;  83 (3) 691-698
    Google Scholar
  • 5 Rand J H. Molecular pathogenesis of the antiphospholipid syndrome.  Circ Res. 2002;  90 (1) 29-37
    Google Scholar
  • 6 Out H J, Kooijman C D, Bruinse H W, Derksen R H. Histopathological findings in placentae from patients with intra-uterine fetal death and anti-phospholipid antibodies.  Eur J Obstet Gynecol Reprod Biol. 1991;  41 (3) 179-186
    Google Scholar
  • 7 Kutteh W H, Rote N S, Silver R. Antiphospholipid antibodies and reproduction: the antiphospholipid antibody syndrome.  Am J Reprod Immunol. 1999;  41 (2) 133-152
    Google Scholar
  • 8 Schust D J, Hill J A. Recurrent Pregnancy Loss. Philadelphia, PA: Lippincott Williams & Wilkins; 2002
    Google Scholar
  • 9 Rand J H. The antiphospholipid syndrome.  Annu Rev Med. 2003;  54 409-424
    Google Scholar
  • 10 Harris E N, Gharavi A E, Boey M L et al.. Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus.  Lancet. 1983;  2 (8361) 1211-1214
    Google Scholar
  • 11 Wasserman A, Neisser A, Bruck C. Eine Serodiagnostiche reaktion bei syphilis.  Dtsch Med Wochenschr. 1906;  32 745-749
    Google Scholar
  • 12 Landsteiner K, Muller R, Potzl D. Studies on the complement binding reaction in syphilis.  Wien Klin Wochenschr. 1907;  20 1565
    Google Scholar
  • 13 Pangborn M C, Pangborn M C. A new seriologically active phospholipid from beef heart.  Proc Soc Exp Biol Med. 1941;  48 484-486
    Google Scholar
  • 14 Moore J E, Mohr C F. Biologically false positive serologic tests for syphilis; type, incidence, and cause.  J Am Med Assoc. 1952;  150 (5) 467-473
    Google Scholar
  • 15 Conley C L, Hartmann R C. A hemorrhagic disorder caused by circulating anticoagulant in patients with disseminated lupus erythematosus.  J Lab Clin Invest. 1952;  31 621-622
    Google Scholar
  • 16 Beaumont J L. Acquired hemorrhagic syndrome caused by a circulating anticoagulant; inhibition of the thromboplastic function of the blood platelets; description of a specific test. [in French].  Sang. 1954;  25 1-5
    Google Scholar
  • 17 Laurell A B, Nilsson I M. Hypergammaglobulinemia, circulating anticoagulant, and biologic false positive Wassermann reaction; a study in two cases.  J Lab Clin Med. 1957;  49 (5) 694-707
    Google Scholar
  • 18 Bowie E J, Thompson Jr J H, Pascuzzi C A, Owen Jr C A. Thrombosis in systemic lupus erythematosus despite circulating anticoagulants.  J Lab Clin Med. 1963;  62 416-430
    Google Scholar
  • 19 Alarcon Segovia D, Osmundson P J. Peripheral vascular syndromes associated with systemic lupus erythematosus.  Ann Intern Med. 1965;  62 907-919
    Google Scholar
  • 20 Lechner K. A new type of coagulation inhibitor.  Thromb Diath Haemorrh. 1969;  21 (3) 482-499
    Google Scholar
  • 21 Feinstein D I, Rapaport S I. Acquired inhibitors of blood coagulation.  Prog Hemost Thromb. 1972;  1 75-95
    Google Scholar
  • 22 Nilsson I M, Astedt B, Hedner U, Berezin D. Intrauterine death and circulating anticoagulant (“antithromboplastin”).  Acta Med Scand. 1975;  197 (3) 153-159
    Google Scholar
  • 23 Von Felton A, Gehrig D, Martius F. Antiphospholipid antibodies as a cause of thrombocytopenia and p-pathia.  Eur J Clin Invest. 1977;  7 223
    Google Scholar
  • 24 Soulier J P, Boffa M C. Avortements à répétition, thromboses et anticoagulant circulant anti-thromboplastine.  Nouv Presse Med. 1980;  9 859-864
    Google Scholar
  • 25 Thiagarajan P, Shapiro S S, De Marco L. Monoclonal immunoglobulin M lambda coagulation inhibitor with phospholipid specificity. Mechanism of a lupus anticoagulant.  J Clin Invest. 1980;  66 (3) 397-405
    Google Scholar
  • 26 Carreras L O, Vermylen J, Spitz B, Van Assche A. “Lupus” anticoagulant and inhibition of prostacyclin formation in patients with repeated abortion, intrauterine growth retardation and intrauterine death.  Br J Obstet Gynaecol. 1981;  88 (9) 890-894
    Google Scholar
  • 27 Hughes G RV. Thrombosis, abortion, cerebral disease, and the lupus anticoagulant.  Br Med J (Clin Res Ed). 1983;  287 (6399) 1088-1089
    Google Scholar
  • 28 Hughes G RV. The anticardiolipin syndrome.  Clin Exp Rheumatol. 1985;  3 (4) 285-286
    Google Scholar
  • 29 Loizou S, McCrea J D, Rudge A C, Reynolds R, Boyle C C, Harris E N. Measurement of anti-cardiolipin antibodies by an enzyme-linked immunosorbent assay (ELISA): standardization and quantitation of results.  Clin Exp Immunol. 1985;  62 (3) 738-745
    Google Scholar
  • 30 Harris E N, Baguley E, Asherson R A, Hughes G RV. Clinical and serological features of the antiphospholipid syndrome (APS).  Br J Rheumatol. 1987;  26 (Suppl 2) 19
    Google Scholar
  • 31 Branch D W, Rote N S, Dostal D A, Scott J R. Association of lupus anticoagulant with antibody against phosphatidylserine.  Clin Immunol Immunopathol. 1987;  42 (1) 63-75
    Google Scholar
  • 32 McNeil H P, Simpson R J, Chesterman C N, Krilis S A. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H).  Proc Natl Acad Sci U S A. 1990;  87 (11) 4120-4124
    Google Scholar
  • 33 Rosove M H, Tabsh K, Wasserstrum N, Howard P, Hahn B H, Kalunian K C. Heparin therapy for pregnant women with lupus anticoagulant or anticardiolipin antibodies.  Obstet Gynecol. 1990;  75 (4) 630-634
    Google Scholar
  • 34 Kutteh W H. Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone.  Am J Obstet Gynecol. 1996;  174 (5) 1584-1589
    Google Scholar
  • 35 Wilson W A, Gharavi A E, Koike T et al.. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop.  Arthritis Rheum. 1999;  42 (7) 1309-1311
    Google Scholar
  • 36 Lockshin M D. Antiphospholipid antibody. Babies, blood clots, biology.  JAMA. 1997;  277 (19) 1549-1551
    Google Scholar
  • 37 Alarcón-Segovia D, Delezé M, Oria C V et al.. Antiphospholipid antibodies and the antiphospholipid syndrome in systemic lupus erythematosus. A prospective analysis of 500 consecutive patients.  Medicine (Baltimore). 1989;  68 (6) 353-365
    Google Scholar
  • 38 Kutteh W H, Lyda E C, Abraham S M, Wacholtz M C. Association of anticardiolipin antibodies and pregnancy loss in women with systemic lupus erythematosus.  Fertil Steril. 1993;  60 (3) 449-455
    Google Scholar
  • 39 Miyakis S, Lockshin M D, Atsumi T et al.. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS).  J Thromb Haemost. 2006;  4 (2) 295-306
    Google Scholar
  • 40 Harris E N. Syndrome of the black swan.  Br J Rheumatol. 1987;  26 (5) 324-326
    Google Scholar
  • 41 American College of Obstetricians and Gynecologists Committee on Practice Bulletins-Obstetrics . ACOG Practice Bulletin No. 118: Antiphospholipid syndrome.  Obstet Gynecol. 2011;  117 (1) 192-199
    Google Scholar
  • 42 Silver R M, Draper M L, Scott J R, Lyon J L, Reading J, Branch D W. Clinical consequences of antiphospholipid antibodies: an historic cohort study.  Obstet Gynecol. 1994;  83 (3) 372-377
    Google Scholar
  • 43 Martin B A, Branch D W, Rodgers G M. Sensitivity of the activated partial thromboplastin time, the dilute Russell's viper venom time, and the kaolin clotting time for the detection of the lupus anticoagulant: a direct comparison using plasma dilutions.  Blood Coagul Fibrinolysis. 1996;  7 (1) 31-38
    Google Scholar
  • 44 Pengo V, Tripodi A, Reber G Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis et al. Update of the guidelines for lupus anticoagulant detection.  J Thromb Haemost. 2009;  7 (10) 1737-1740
    Google Scholar
  • 45 Di Simone N, Meroni P L, de Papa N et al.. Antiphospholipid antibodies affect trophoblast gonadotropin secretion and invasiveness by binding directly and through adhered beta2-glycoprotein I.  Arthritis Rheum. 2000;  43 (1) 140-150
    Google Scholar
  • 46 McIntyre J A. Immune recognition at the maternal-fetal interface: overview.  Am J Reprod Immunol. 1992;  28 (3–4) 127-131
    Google Scholar
  • 47 Schousboe I, Rasmussen M S. Synchronized inhibition of the phospholipid mediated autoactivation of factor XII in plasma by beta 2-glycoprotein I and anti-beta 2-glycoprotein I.  Thromb Haemost. 1995;  73 (5) 798-804
    Google Scholar
  • 48 Gleicher N, el-Roeiy A, Confino E, Friberg J. Reproductive failure because of autoantibodies: unexplained infertility and pregnancy wastage.  Am J Obstet Gynecol. 1989;  160 (6) 1376-1380; discussion 1380–1385
    Google Scholar
  • 49 Matzner W, Chong P, Xu G, Ching W. Characterization of antiphospholipid antibodies in women with recurrent spontaneous abortions.  J Reprod Med. 1994;  39 (1) 27-30
    Google Scholar
  • 50 Gilman-Sachs A, Lubinski J, Beer A E, Brend S, Beaman K D. Patterns of anti-phospholipid antibody specificities.  J Clin Lab Immunol. 1991;  35 (2) 83-88
    Google Scholar
  • 51 Branch D W, Silver R, Pierangeli S S, van Leeuwen I, Harris E N. Antiphospholipid antibodies other than lupus anticoagulant and anticardiolipin antibodies in women with recurrent pregnancy loss, fertile controls, and antiphospholipid syndrome.  Obstet Gynecol. 1997;  89 (4) 549-555
    Google Scholar
  • 52 Yetman D L, Kutteh W H. Antiphospholipid antibody panels and recurrent pregnancy loss: prevalence of anticardiolipin antibodies compared with other antiphospholipid antibodies.  Fertil Steril. 1996;  66 (4) 540-546
    Google Scholar
  • 53 Kutteh W H, Corey A, Jaslow C R. Antiphospholipid antibodies and recurrent pregnancy loss: Prevalence of anticardiolipin antibodies, the lupus anticoagulant, and antiphosphatidyl serine antibodies.  Lupus. 2010;  19 546
    Google Scholar
  • 54 Peaceman A M, Silver R M, MacGregor S N, Socol M L. Interlaboratory variation in antiphospholipid antibody testing.  Am J Obstet Gynecol. 1992;  166 1780-1784
    Google Scholar
  • 55 Carreras L O, Forastiero R R, Martinuzzo M E. Which are the best biological markers of the antiphospholipid syndrome?.  J Autoimmun. 2000;  15 (2) 163-172
    Google Scholar
  • 56 Kutteh W H, Franklin R D. Assessing the variation in antiphospholipid antibody (APA) assays: comparison of results from 10 centers.  Am J Obstet Gynecol. 2004;  191 (2) 440-448
    Google Scholar
  • 57 Franklin R D, Kutteh W H. Effects of unfractionated and low molecular weight heparin on antiphospholipid antibody binding in vitro.  Obstet Gynecol. 2003;  101 (3) 455-462
    Google Scholar
  • 58 Franklin R D, Kutteh W H. Antiphospholipid antibodies (APA) and recurrent pregnancy loss: treating a unique APA positive population.  Hum Reprod. 2002;  17 (11) 2981-2985
    Google Scholar
  • 59 Eby C. Antiphospholipid syndrome review.  Clin Lab Med. 2009;  29 (2) 305-319
    Google Scholar
  • 60 Rodger M A. Thrombophilia and placenta-mediated pregnancy complications: from the bench to bedside to policy.  Thromb Res. 2009;  123 (Suppl 2) S100-S104
    Google Scholar
  • 61 Benedetto C, Marozio L, Tavella A M, Salton L, Grivon S, Di Giampaolo F. Coagulation disorders in pregnancy: acquired and inherited thrombophilias.  Ann N Y Acad Sci. 2010;  1205 106-117
    Google Scholar
  • 62 Hatasaka H H. Recurrent miscarriage: epidemiologic factors, definitions, and incidence.  Clin Obstet Gynecol. 1994;  37 (3) 625-634
    Google Scholar
  • 63 Branch D W, Carson S A. The American College of Obstetricians and Gynecologists. Management of Recurrent Early Pregnancy Loss. Washington, DC: The American College of Obstetricians and Gynecologists; 2001. ACOG Practice Bulletin No. 24
    Google Scholar
  • 64 Jaslow C R, Carney J L, Kutteh W H. Diagnostic factors identified in 1020 women with two versus three or more recurrent pregnancy losses.  Fertil Steril. 2010;  93 (4) 1234-1243
    Google Scholar
  • 65 Allison J L, Schust D J. Recurrent first trimester pregnancy loss: revised definitions and novel causes.  Curr Opin Endocrinol Diabetes Obes. 2009;  16 (6) 446-450
    Google Scholar
  • 66 Vinatier D, Dufour P, Cosson M, Houpeau J L. Antiphospholipid syndrome and recurrent miscarriages.  Eur J Obstet Gynecol Reprod Biol. 2001;  96 (1) 37-50
    Google Scholar
  • 67 Chauleur C, Galanaud J P, Alonso S et al.. Observational study of pregnant women with a previous spontaneous abortion before the 10th gestation week with and without antiphospholipid antibodies.  J Thromb Haemost. 2010;  8 (4) 699-706
    Google Scholar
  • 68 Vora S, Shetty S, Ghosh K. Thrombophilic dimension of recurrent fetal loss in Indian patients.  Blood Coagul Fibrinolysis. 2008;  19 (6) 581-584
    Google Scholar
  • 69 Oron G, Ben-Haroush A, Goldfarb R, Molad Y, Hod M, Bar J. Contribution of the addition of anti-β2-glycoprotein to the classification of antiphospholipid syndrome in predicting adverse pregnancy outcome.  J Matern Fetal Neonatal Med. 2011;  24 (4) 606-609
    Google Scholar
  • 70 Abrahams V M. Mechanisms of antiphospholipid antibody-associated pregnancy complications.  Thromb Res. 2009;  124 (5) 521-525
    Google Scholar
  • 71 Ziakas P D, Pavlou M, Voulgarelis M. Heparin treatment in antiphospholipid syndrome with recurrent pregnancy loss: a systematic review and meta-analysis.  Obstet Gynecol. 2010;  115 (6) 1256-1262
    Google Scholar
  • 72 Hoppe B, Burmester G R, Dörner T. Heparin or aspirin or both in the treatment of recurrent abortions in women with antiphospholipid antibody (syndrome).  Curr Opin Rheumatol. 2011;  23 (3) 299-304
    Google Scholar
  • 73 Backos M, Rai R, Baxter N, Chilcott I T, Cohen H, Regan L. Pregnancy complications in women with recurrent miscarriage associated with antiphospholipid antibodies treated with low dose aspirin and heparin.  Br J Obstet Gynaecol. 1999;  106 (2) 102-107
    Google Scholar
  • 74 Branch D W, Khamashta M A. Antiphospholipid syndrome: obstetric diagnosis, management, and controversies.  Obstet Gynecol. 2003;  101 (6) 1333-1344
    Google Scholar
  • 75 Robertson L, Wu O, Langhorne P Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) Study et al. Thrombophilia in pregnancy: a systematic review.  Br J Haematol. 2006;  132 (2) 171-196
    Google Scholar
  • 76 Alfirevic Z, Roberts D, Martlew V. How strong is the association between maternal thrombophilia and adverse pregnancy outcome? A systematic review.  Eur J Obstet Gynecol Reprod Biol. 2002;  101 (1) 6-14
    Google Scholar
  • 77 Ruffatti A, Tonello M, Cavazzana A, Bagatella P, Pengo V. Laboratory classification categories and pregnancy outcome in patients with primary antiphospholipid syndrome prescribed antithrombotic therapy.  Thromb Res. 2009;  123 (3) 482-487
    Google Scholar
  • 78 Werner E F, Lockwood C J. Thrombophilias and stillbirth.  Clin Obstet Gynecol. 2010;  53 (3) 617-627
    Google Scholar
  • 79 Nodler J, Moolamalla S R, Ledger E M, Nuwayhid B S, Mulla Z D. Elevated antiphospholipid antibody titers and adverse pregnancy outcomes: analysis of a population-based hospital dataset.  BMC Pregnancy Childbirth. 2009;  9 11-18
    Google Scholar
  • 80 do Prado A, Piovesan D, Staub H, Horta B L. Association of anticardiolipin antibodies with pre-eclampsia: a systematic review and meta-analysis.  Obstet Gynecol. 2010;  116 1433-1443
    Google Scholar
  • 81 Heilmann L, Schorsch M, Hahn T, Fareed J. Antiphospholipid syndrome and pre-eclampsia.  Semin Thromb Hemost. 2011;  37 (2) 141-145
    Google Scholar
  • 82 Branch D W, Silver R M, Blackwell J L, Reading J C, Scott J R. Outcome of treated pregnancies in women with antiphospholipid syndrome: an update of the Utah experience.  Obstet Gynecol. 1992;  80 (4) 614-620
    Google Scholar
  • 83 Cowchock F S, Reece E A, Balaban D, Branch D W, Plouffe L. Repeated fetal losses associated with antiphospholipid antibodies: a collaborative randomized trial comparing prednisone with low-dose heparin treatment.  Am J Obstet Gynecol. 1992;  166 (5) 1318-1323
    Google Scholar
  • 84 Laskin C A, Bombardier C, Hannah M E et al.. Prednisone and aspirin in women with autoantibodies and unexplained recurrent fetal loss.  N Engl J Med. 1997;  337 (3) 148-153
    Google Scholar
  • 85 Kutteh W H, Ermel L D. A clinical trial for the treatment of antiphospholipid antibody-associated recurrent pregnancy loss with lower dose heparin and aspirin.  Am J Reprod Immunol. 1996;  35 (4) 402-407
    Google Scholar
  • 86 Empson M, Lassere M, Craig J C, Scott J R. Recurrent pregnancy loss with antiphospholipid antibody: a systematic review of therapeutic trials.  Obstet Gynecol. 2002;  99 (1) 135-144
    Google Scholar
  • 87 Lima F, Khamashta M A, Buchanan N M, Kerslake S, Hunt B J, Hughes G R. A study of sixty pregnancies in patients with the antiphospholipid syndrome.  Clin Exp Rheumatol. 1996;  14 (2) 131-136
    Google Scholar
  • 88 Yasuda M, Takakuwa K, Tokunaga A, Tanaka K. Prospective studies of the association between anticardiolipin antibody and outcome of pregnancy.  Obstet Gynecol. 1995;  86 (4 Pt 1) 555-559
    Google Scholar
  • 89 Motta M, Lachassinne E, Boffa M C et al.. European registry of infants born to mothers with antiphospholipid syndrome: preliminary results.  Minerva Pediatr. 2010;  62 (3, Suppl 1) 25-27
    Google Scholar
  • 90 Levine J S, Branch D W, Rauch J. The antiphospholipid syndrome.  N Engl J Med. 2002;  346 (10) 752-763
    Google Scholar
  • 91 Tincani A, Balestrieri G, Danieli E et al.. Pregnancy complications of the antiphospholipid syndrome.  Autoimmunity. 2003;  36 (1) 27-32
    Google Scholar
  • 92 Meroni P L, Riboldi P. Pathogenic mechanisms mediating antiphospholipid syndrome.  Curr Opin Rheumatol. 2001;  13 (5) 377-382
    Google Scholar
  • 93 Branch D W, Dudley D J, Mitchell M D et al.. Immunoglobulin G fractions from patients with antiphospholipid antibodies cause fetal death in BALB/c mice: a model for autoimmune fetal loss.  Am J Obstet Gynecol. 1990;  163 (1 Pt 1) 210-216
    Google Scholar
  • 94 Blank M, Cohen J, Toder V, Shoenfeld Y. Induction of antiphospholipid syndrome in naive mice with mouse lupus monoclonal and human polyclonal anti-cardiolipin antibodies.  Proc Natl Acad Sci U S A. 2001;  88 3069-3073
    Google Scholar
  • 95 Piona A, La Rosa L, Tincani A et al.. Placental thrombosis and fetal loss after passive transfer of mouse lupus monoclonal or human polyclonal anti-cardiolipin antibodies in pregnant naive BALB/c mice.  Scand J Immunol. 1995;  41 (5) 427-432
    Google Scholar
  • 96 Ornoy A, Yacobi S, Matalon S T et al.. The effects of antiphospholipid antibodies obtained from women with SLE/APS and associated pregnancy loss on rat embryos and placental explants in culture.  Lupus. 2003;  12 (7) 573-578
    Google Scholar
  • 97 Hanly J G, Gladman D D, Rose T H, Laskin C A, Urowitz M B. Lupus pregnancy. A prospective study of placental changes.  Arthritis Rheum. 1988;  31 (3) 358-366
    Google Scholar
  • 98 Nayar R, Lage J M. Placental changes in a first trimester missed abortion in maternal systemic lupus erythematosus with antiphospholipid syndrome; a case report and review of the literature.  Hum Pathol. 1996;  27 (2) 201-206
    Google Scholar
  • 99 Turiel M, Sarzi-Puttini P, Peretti R et al.. Thrombotic risk factors in primary antiphospholipid syndrome: a 5-year prospective study.  Stroke. 2005;  36 (7) 1490-1494
    Google Scholar
  • 100 Gharavi A E, Pierangeli S S, Espinola R G, Liu X, Colden-Stanfield M, Harris E N. Antiphospholipid antibodies induced in mice by immunization with a cytomegalovirus-derived peptide cause thrombosis and activation of endothelial cells in vivo.  Arthritis Rheum. 2002;  46 (2) 545-552
    Google Scholar
  • 101 Galli M, Luciani D, Bertolini G, Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature.  Blood. 2003;  101 (5) 1827-1832
    Google Scholar
  • 102 Peaceman A M, Rehnberg K A. The effect of immunoglobulin G fractions from patients with lupus anticoagulant on placental prostacyclin and thromboxane production.  Am J Obstet Gynecol. 1993;  169 (6) 1403-1406
    Google Scholar
  • 103 Cariou R, Tobelem G, Soria C, Caen J. Inhibition of protein C activation by endothelial cells in the presence of lupus anticoagulant.  N Engl J Med. 1986;  314 (18) 1193-1194
    Google Scholar
  • 104 Cosgriff T M, Martin B A. Low functional and high antigenic antithrombin III level in a patient with the lupus anticoagulant and recurrent thrombosis.  Arthritis Rheum. 1981;  24 (1) 94-96
    Google Scholar
  • 105 Vogt E, Ng A K, Rote N S. A model for the antiphospholipid antibody syndrome: monoclonal antiphosphatidylserine antibody induces intrauterine growth restriction in mice.  Am J Obstet Gynecol. 1996;  174 (2) 700-707
    Google Scholar
  • 106 Robertson S A, Roberts C T, van Beijering E et al.. Effect of beta2-glycoprotein I null mutation on reproductive outcome and antiphospholipid antibody-mediated pregnancy pathology in mice.  Mol Hum Reprod. 2004;  10 (6) 409-416
    Google Scholar
  • 107 Yasuda S, Tsutsumi A, Chiba H et al.. beta(2)-glycoprotein I deficiency: prevalence, genetic background and effects on plasma lipoprotein metabolism and hemostasis.  Atherosclerosis. 2000;  152 (2) 337-346
    Google Scholar
  • 108 Rand J H, Wu X X, Quinn A S, Taatjes D J. The annexin A5-mediated pathogenic mechanism in the antiphospholipid syndrome: role in pregnancy losses and thrombosis.  Lupus. 2010;  19 (4) 460-469
    Google Scholar
  • 109 Rand J H, Wu X X, Andree H A et al.. Pregnancy loss in the antiphospholipid-antibody syndrome—a possible thrombogenic mechanism.  N Engl J Med. 1997;  337 (3) 154-160
    Google Scholar
  • 110 Out H J, Bruinse H W, Christiaens G C et al.. A prospective, controlled multicenter study on the obstetric risks of pregnant women with antiphospholipid antibodies.  Am J Obstet Gynecol. 1992;  167 (1) 26-32
    Google Scholar
  • 111 Salafia C M, Cowchock F S. Placental pathology and antiphospholipid antibodies: a descriptive study.  Am J Perinatol. 1997;  14 (8) 435-441
    Google Scholar
  • 112 Greaves M, Cohen H, MacHin S J, Mackie I. Guidelines on the investigation and management of the antiphospholipid syndrome.  Br J Haematol. 2000;  109 (4) 704-715
    Google Scholar
  • 113 Sebire N J, Fox H, Backos M, Rai R, Paterson C, Regan L. Defective endovascular trophoblast invasion in primary antiphospholipid antibody syndrome-associated early pregnancy failure.  Hum Reprod. 2002;  17 (4) 1067-1071
    Google Scholar
  • 114 Di Simone N, Caliandro D, Castellani R, Ferrazzani S, De Carolis S, Caruso A. Low-molecular weight heparin restores in-vitro trophoblast invasiveness and differentiation in presence of immunoglobulin G fractions obtained from patients with antiphospholipid syndrome.  Hum Reprod. 1999;  14 (2) 489-495
    Google Scholar
  • 115 Sthoeger Z M, Mozes E, Tartakovsky B. Anti-cardiolipin antibodies induce pregnancy failure by impairing embryonic implantation.  Proc Natl Acad Sci U S A. 1993;  90 (14) 6464-6467
    Google Scholar
  • 116 Di Simone N, Castellani R, Caliandro D, Caruso A. Antiphospholid antibodies regulate the expression of trophoblast cell adhesion molecules.  Fertil Steril. 2002;  77 (4) 805-811
    Google Scholar
  • 117 Tedesco F, Narchi G, Radillo O, Meri S, Ferrone S, Betterle C. Susceptibility of human trophoblast to killing by human complement and the role of the complement regulatory proteins.  J Immunol. 1993;  151 (3) 1562-1570
    Google Scholar
  • 118 Holers V M, Girardi G, Mo L et al.. Complement C3 activation is required for antiphospholipid antibody-induced fetal loss.  J Exp Med. 2002;  195 (2) 211-220
    Google Scholar
  • 119 Girardi G, Berman J, Redecha P et al.. Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome.  J Clin Invest. 2003;  112 (11) 1644-1654
    Google Scholar
  • 120 Salmon J E, Girardi G. The role of complement in the antiphospholipid syndrome.  Curr Dir Autoimmun. 2004;  7 133-148
    Google Scholar
  • 121 Berman J, Girardi G, Salmon J E. TNF-alpha is a critical effector and a target for therapy in antiphospholipid antibody-induced pregnancy loss.  J Immunol. 2005;  174 (1) 485-490
    Google Scholar
  • 122 Blank M, Krause I, Wildbaum G, Karin N, Shoenfeld Y. TNFalpha DNA vaccination prevents clinical manifestations of experimental antiphospholipid syndrome.  Lupus. 2003;  12 (7) 546-549
    Google Scholar
  • 123 Boles J, Mackman N. Role of tissue factor in thrombosis in antiphospholipid antibody syndrome.  Lupus. 2010;  19 (4) 370-378
    Google Scholar
  • 124 Alijotas-Reig J, Vilardell-Tarres M. Is obstetric antiphospholipid syndrome a primary nonthrombotic, proinflammatory, complement-mediated disorder related to antiphospholipid antibodies?.  Obstet Gynecol Surv. 2010;  65 (1) 39-45
    Google Scholar
  • 125 Stone S, Pijnenborg R, Vercruysse L et al.. The placental bed in pregnancies complicated by primary antiphospholipid syndrome.  Placenta. 2006;  27 (4–5) 457-467
    Google Scholar
  • 126 Cavazzana I, Manuela N, Irene C et al.. Complement activation in anti-phospholipid syndrome: a clue for an inflammatory process?.  J Autoimmun. 2007;  28 (2–3) 160-164
    Google Scholar
  • 127 Girardi G, Redecha P, Salmon J E. Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation.  Nat Med. 2004;  10 (11) 1222-1226
    Google Scholar
  • 128 Di Simone N, Castellani R, Raschi E, Borghi M O, Meroni P L, Caruso A. Anti-β-2 glycoprotein I antibodies affect Bcl-2 and Bax trophoblast expression without evidence of apoptosis.  Ann N Y Acad Sci. 2006;  1069 364-376
    Google Scholar
  • 129 Di Simone N, Di Nicuolo F, Sanguinetti M et al.. Low-molecular weight heparin induces in vitro trophoblast invasiveness: role of matrix metalloproteinases and tissue inhibitors.  Placenta. 2007;  28 (4) 298-304
    Google Scholar
  • 130 Ermel L D, Marshburn P B, Kutteh W H. Interaction of heparin with antiphospholipid antibodies (APA) from the sera of women with recurrent pregnancy loss (RPL).  Am J Reprod Immunol. 1995;  33 (1) 14-20
    Google Scholar
  • 131 Stephenson M D, Houlihan E, Tsang P, Ensworth S, Lim K, Ballem P J. Concomitant use of IVIG for treatment of the antiphospholipid antibody syndrome (APS) when ASA and heparin results in at least one adverse pregnancy outcome.  Lupus. 2002;  11 694
    Google Scholar
  • 132 Nelson-Piercy C, Letsky E A, de Swiet M. Low-molecular-weight heparin for obstetric thromboprophylaxis: experience of sixty-nine pregnancies in sixty-one women at high risk.  Am J Obstet Gynecol. 1997;  176 (5) 1062-1068
    Google Scholar
  • 133 Brenner B, Hoffman R, Blumenfeld Z, Weiner Z, Younis J S. Gestational outcome in thrombophilic women with recurrent pregnancy loss treated by enoxaparin.  Thromb Haemost. 2000;  83 (5) 693-697
    Google Scholar
  • 134 Farquharson R G, Quenby S, Greaves M. Antiphospholipid syndrome in pregnancy: a randomized, controlled trial of treatment.  Obstet Gynecol. 2002;  100 (3) 408-413
    Google Scholar
  • 135 Stephenson M D, Ballem P J, Tsang P et al.. Treatment of antiphospholipid antibody syndrome (APS) in pregnancy: a randomized pilot trial comparing low molecular weight heparin to unfractionated heparin.  J Obstet Gynaecol Can. 2004;  26 (8) 729-734
    Google Scholar
  • 136 Noble L S, Kutteh W H, Lashey N, Franklin R D, Herrada J. Antiphospholipid antibodies associated with recurrent pregnancy loss: prospective, multicenter, controlled pilot study comparing treatment with low-molecular-weight heparin versus unfractionated heparin.  Fertil Steril. 2005;  83 (3) 684-690
    Google Scholar
  • 137 Erkan D, Merrill J T, Yazici Y, Sammaritano L, Buyon J P, Lockshin M D. High thrombosis rate after fetal loss in antiphospholipid syndrome: effective prophylaxis with aspirin.  Arthritis Rheum. 2001;  44 (6) 1466-1467
    Google Scholar
  • 138 Sher G, Feinman M, Zouves C et al.. High fecundity rates following in-vitro fertilization and embryo transfer in antiphospholipid antibody seropositive women treated with heparin and aspirin.  Hum Reprod. 1994;  9 2278-2283
    Google Scholar
  • 139 Balasch J, Creus M, Fábregues F et al.. Antiphospholipid antibodies and human reproductive failure.  Hum Reprod. 1996;  11 (10) 2310-2315
    Google Scholar
  • 140 Geva E, Amit A, Lerner-Geva L, Lessing J B. Autoimmunity and reproduction.  Fertil Steril. 1997;  67 (4) 599-611
    Google Scholar
  • 141 Hornstein M D. Antiphospholipid antibodies in patients undergoing IVF: the data do not support testing.  Fertil Steril. 2000;  74 (4) 635-636
    Google Scholar
  • 142 Silver R M, Draper M L, Scott J R, Lyon J L, Reading J, Branch D W. Clinical consequences of antiphospholipid antibodies: an historic cohort study.  Obstet Gynecol. 1994;  83 (3) 372-377
    Google Scholar
  • 143 Rai R, Cohen H, Dave M, Regan L. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies).  BMJ. 1997;  314 (7076) 253-257
    Google Scholar
  • 144 Branch D W, Peaceman A M, Druzin M The Pregnancy Loss Study Group et al. A multicenter, placebo-controlled pilot study of intravenous immune globulin treatment of antiphospholipid syndrome during pregnancy.  Am J Obstet Gynecol. 2000;  182 (1 Pt 1) 122-127
    Google Scholar
  • 145 Pattison N S, Chamley L W, Birdsall M, Zanderigo A M, Liddell H S, McDougall J. Does aspirin have a role in improving pregnancy outcome for women with the antiphospholipid syndrome? A randomized controlled trial.  Am J Obstet Gynecol. 2000;  183 (4) 1008-1012
    Google Scholar
  • 146 Triolo G, Ferrante A, Ciccia F et al.. Randomized study of subcutaneous low molecular weight heparin plus aspirin versus intravenous immunoglobulin in the treatment of recurrent fetal loss associated with antiphospholipid antibodies.  Arthritis Rheum. 2003;  48 (3) 728-731
    Google Scholar
  • 147 Goel N, Tuli A, Choudhry R. The role of aspirin versus aspirin and heparin in cases of recurrent abortions with raised anticardiolipin antibodies.  Med Sci Monit. 2006;  12 (3) CR132-CR136
    Google Scholar
  • 148 Laskin C A, Spitzer K A, Clark C A et al.. Low molecular weight heparin and aspirin for recurrent pregnancy loss: results from the randomized, controlled HepASA Trial.  J Rheumatol. 2009;  36 (2) 279-287
    Google Scholar

William H. KuttehM.D. Ph.D. H.C.L.D. 

Department of Obstetrics and Gynecology; Director, Division of Reproductive Endocrinology and Infertility

University of Tennessee Health Science Center, 80 Humphreys Center, Suite 307, Memphis, TN 38120

Email: wkutteh@uthsc.edu